FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2084493274> ?p ?o ?g. }

• W2084493274 abstract "To examine the baseline metabolic monitoring (MetMon) for second generation antipsychotics (SGA) among patients with schizophrenia in the Veterans Integrated Service Network (VISN) 16 of the Veterans Health Administration (VHA). VISN16 electronic medical records for 10/2002-08/2005 were used to identify patients with schizophrenia who received a new episode of SGA treatment after 10/2003, in which the VISN 16 baseline MetMon program was implemented. Patients who underwent MetMon (MetMon+: either blood glucose or lipid testing records) were compared with patients who did not (MetMon-), on patient characteristics and resource utilization in the year prior to index treatment episode. A parsimonious logistic regression was used to identify predictors for MetMon+ with adjusted odds ratios (OR) and 95% confidence intervals (CI). Out of 4,709 patients, 3,568 (75.8%) underwent the baseline MetMon. Compared with the MetMon- group, the MetMon+ patients were found more likely to have baseline diagnoses or mediations for diabetes (OR [CI]: 2.336 [1.846-2.955]), dyslipidemia (2.439 [2.029-2.932]), and hypertension (1.497 [1.287-1.743]), substance use disorders (1.460 [1.257-1.696]), or to be recorded as obesity (2.052 [1.724-2.443]). Increased likelihood for monitoring were positively associated with number of antipsychotics during the previous year (FGA: 1.434 [1.129-1.821]; SGA: 1.503 [1.290-1.751]). Other significant predictors for monitoring were more augmentation episodes (1.580 [1.145-2.179]), more outpatient visits (1.007 [1.002-1.013])), hospitalization days (1.011 [1.007-1.015]), and longer duration of antipsychotic use (1.001 [1.001-1.001]). Among the MetMon+ group, approximately 38.9% patient had metabolic syndrome. This wide time window of 180 days, although congruent with the VHA guidelines for the baseline MetMon process, needs to be re-evaluated and narrowed down, so that optimally the monitoring event occurs at the time of receiving a new episode of SGA treatment. Future research will examine whether or not patients prescribed an SGA are assessed for metabolic syndrome following the index episode of antipsychotic therapy, and whether or not such baseline and follow-up monitoring programs in routine care are cost-effective. The baseline MetMon has been performed for a majority of the VISN 16 patients with schizophrenia prior to index SGA over the study period. Compared with MetMon- group, MetMon+ patients were more likely to be obese and manifest a more severe illness profile." @default.
• W2084493274 created "2016-06-24" @default.
• W2084493274 creator A5001716663 @default.
• W2084493274 creator A5011706362 @default.
• W2084493274 creator A5014897722 @default.
• W2084493274 creator A5019687777 @default.
• W2084493274 creator A5034671525 @default.
• W2084493274 creator A5069523303 @default.
• W2084493274 date "2009-12-01" @default.
• W2084493274 modified "2023-10-03" @default.
• W2084493274 title "Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration" @default.
• W2084493274 cites W1484975190 @default.
• W2084493274 cites W1986376350 @default.
• W2084493274 cites W1989361442 @default.
• W2084493274 cites W2000445173 @default.
• W2084493274 cites W2014364697 @default.
• W2084493274 cites W2014558798 @default.
• W2084493274 cites W2018787128 @default.
• W2084493274 cites W2025380847 @default.
• W2084493274 cites W2047660590 @default.
• W2084493274 cites W2062359581 @default.
• W2084493274 cites W2066051121 @default.
• W2084493274 cites W2080110721 @default.
• W2084493274 cites W2088209318 @default.
• W2084493274 cites W2094980364 @default.
• W2084493274 cites W2101762862 @default.
• W2084493274 cites W2107325590 @default.
• W2084493274 cites W2123289485 @default.
• W2084493274 cites W2146830005 @default.
• W2084493274 cites W2170498560 @default.
• W2084493274 cites W2185461071 @default.
• W2084493274 cites W2194109317 @default.
• W2084493274 cites W4242811026 @default.
• W2084493274 cites W56588941 @default.
• W2084493274 doi "https://doi.org/10.1186/1471-244x-9-80" @default.
• W2084493274 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2807859" @default.
• W2084493274 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20021664" @default.
• W2084493274 hasPublicationYear "2009" @default.
• W2084493274 type Work @default.
• W2084493274 sameAs 2084493274 @default.
• W2084493274 citedByCount "25" @default.
• W2084493274 countsByYear W20844932742012 @default.
• W2084493274 countsByYear W20844932742013 @default.
• W2084493274 countsByYear W20844932742014 @default.
• W2084493274 countsByYear W20844932742015 @default.
• W2084493274 countsByYear W20844932742016 @default.
• W2084493274 countsByYear W20844932742017 @default.
• W2084493274 countsByYear W20844932742018 @default.
• W2084493274 countsByYear W20844932742019 @default.
• W2084493274 countsByYear W20844932742020 @default.
• W2084493274 countsByYear W20844932742021 @default.
• W2084493274 countsByYear W20844932742022 @default.
• W2084493274 countsByYear W20844932742023 @default.
• W2084493274 crossrefType "journal-article" @default.
• W2084493274 hasAuthorship W2084493274A5001716663 @default.
• W2084493274 hasAuthorship W2084493274A5011706362 @default.
• W2084493274 hasAuthorship W2084493274A5014897722 @default.
• W2084493274 hasAuthorship W2084493274A5019687777 @default.
• W2084493274 hasAuthorship W2084493274A5034671525 @default.
• W2084493274 hasAuthorship W2084493274A5069523303 @default.
• W2084493274 hasBestOaLocation W20844932741 @default.
• W2084493274 hasConcept C118552586 @default.
• W2084493274 hasConcept C126322002 @default.
• W2084493274 hasConcept C134018914 @default.
• W2084493274 hasConcept C151956035 @default.
• W2084493274 hasConcept C156957248 @default.
• W2084493274 hasConcept C160735492 @default.
• W2084493274 hasConcept C162324750 @default.
• W2084493274 hasConcept C187212893 @default.
• W2084493274 hasConcept C194828623 @default.
• W2084493274 hasConcept C195910791 @default.
• W2084493274 hasConcept C2776412080 @default.
• W2084493274 hasConcept C2778096610 @default.
• W2084493274 hasConcept C2780494398 @default.
• W2084493274 hasConcept C3019952477 @default.
• W2084493274 hasConcept C44249647 @default.
• W2084493274 hasConcept C50522688 @default.
• W2084493274 hasConcept C511355011 @default.
• W2084493274 hasConcept C555293320 @default.
• W2084493274 hasConcept C71924100 @default.
• W2084493274 hasConceptScore W2084493274C118552586 @default.
• W2084493274 hasConceptScore W2084493274C126322002 @default.
• W2084493274 hasConceptScore W2084493274C134018914 @default.
• W2084493274 hasConceptScore W2084493274C151956035 @default.
• W2084493274 hasConceptScore W2084493274C156957248 @default.
• W2084493274 hasConceptScore W2084493274C160735492 @default.
• W2084493274 hasConceptScore W2084493274C162324750 @default.
• W2084493274 hasConceptScore W2084493274C187212893 @default.
• W2084493274 hasConceptScore W2084493274C194828623 @default.
• W2084493274 hasConceptScore W2084493274C195910791 @default.
• W2084493274 hasConceptScore W2084493274C2776412080 @default.
• W2084493274 hasConceptScore W2084493274C2778096610 @default.
• W2084493274 hasConceptScore W2084493274C2780494398 @default.
• W2084493274 hasConceptScore W2084493274C3019952477 @default.
• W2084493274 hasConceptScore W2084493274C44249647 @default.
• W2084493274 hasConceptScore W2084493274C50522688 @default.
• W2084493274 hasConceptScore W2084493274C511355011 @default.
• W2084493274 hasConceptScore W2084493274C555293320 @default.
• W2084493274 hasConceptScore W2084493274C71924100 @default.
• W2084493274 hasIssue "1" @default.

• next